Safety and effectiveness of insulin detemir in different age-groups in the A1chieve study

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 77-90

  Malek, Rachid ^a   Gonzalez Galvez, Guillermo ^b   El Naggar, Nabil ^c   Shah, Siddharth ^d   Prusty, Vinay ^e   Litwak, Leon ^f  

^a Setif 1 University   (Algeria)

^b Instituto Jalisciense de Investigacion en Diabetes y Obesidad   (Mexico)

^c Hai Aljamea Hospital   (Saudi Arabia)

^d Bhatia Hospital   (India)

^e Novo Nordisk FemCare AG   (Switzerland)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Hypoglycemia; Insulin detemir; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARBOHYDRATE INTAKE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; WEIGHT REDUCTION;

EID: 84899867146     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0021-3     Document Type: Article

References (24)

1. International Diabetes Federation. IDF Diabetes Atlas 2012 Update, 5th edn. Brussels, Belgium; 2012.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
4. International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, Belgium; 2012.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
6. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence (NICE) Guidelines. Type 2 diabetes: the management of type 2 diabetes; 2008.
7. Olson DE, Norris SL. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics. 2004;59:18-24 quiz 5.
8. Plank J, Bodenlenz M, Sinner F, et al. A doubleblind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-12.
9. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable timeaction profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-9.
10. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648-59.
11. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569-81.
12. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269-74.
13. Khunti K, Caputo S, Damci T, et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012. doi: 10.1111/j.1463-1326.2012.01665.x.
14. Perriello G, Caputo S, De Pergola G, et al. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. Expert Opin Pharmacother. 2011;12:2449-55.
15. Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94:352-63.
16. Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract. 2011;94:364-70.
17. International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Revision 2; 2007.
18. World Medical Association. Declaration of Helsinki-ethical principles for medical research involving human subjects 2008. http://www.riip-influenza.org/wp-content/uploads/2011/08/Helsinki-2008-EN.pdf. Accessed 8 Nov 2011.
19. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
20. Chan TY. Estimates on the incidence of antidiabetic drug-induced severe hypoglycaemia in Hong Kong. Pharmacoepidemiol Drug Saf. 1998;7:411-4.
21. Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51:S265-80.
22. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. Diabet Med. 2012;29:293-302.
23. Jacobson AM. Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract. 2004;10:502-8.
24. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086-91.